New Appointment

(Chicago, Illinois) — March 10, 2025
ExoMira Medicine is excited to welcome Yan He as Director of Business and Clinical Development, further strengthening the company’s translational and operational capabilities as it advances toward clinical development of its lead immunotherapy candidate, MIRA-1.

Yan brings deep cross-sector experience across biopharma, academic research, and strategy consulting. He has led and supported clinical programs from Phase 1 through Phase 4 across diverse therapeutic areas including oncology, hematology, vaccines, respiratory, neuropsychiatric disorders, and metabolic diseases. He has successfully overseen trial design, clinical operations, portfolio strategy, and regulatory engagements, including direct interactions with the FDA and Health Canada.

Prior to joining ExoMira, Yan held roles at Pfizer, Oliver Wyman, Ottawa Hospital Research Institute, and several advisory and consulting positions where he combined scientific acumen with data-driven business strategy. He is also an alum of the Kellogg & McCormick MBAi program at Northwestern University, which blends business leadership with technical training in AI and machine learning. He also holds a Master’s in Clinical Research Administration from George Washington University and a BSc in Pharmacology & Toxicology from McGill University.